SecBot SecBot
SECBOTREPLAY Home › Report › DRTSW

DRTSW · Alpha Tau Medical Ltd

Alpha Tau Medical Ltd. · 6-K filed May 8, 2026 at 09:10 ET

At the news

NEUTRALIMPACT 3/10

6-K filed May 8, 2026 at 09:10 ET

Alpha Tau Medical Ltd. filed a 6-K on May 8, 2026, announcing a conference call to discuss interim clinical data from the first three patients treated in its REGAIN trial for recurrent glioblastoma. The filing is a routine update on early-stage clinical progress with no financial data or material corporate events disclosed.

  • Conference call scheduled for May 11, 2026 at 8:30am ET to discuss interim data from first three patients in REGAIN trial.
  • REGAIN trial is a U.S. study for recurrent glioblastoma not amenable to surgical resection, expected to enroll up to ten patients.
  • No financial results, guidance, or material agreements were disclosed in the filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access